Description
Variant summary: TP53 c.28G>A (p.Val10Ile) results in a conservative amino acid change located in the p53 transactivation domain (IPR013872) of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 3.2e-05 in 250780 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.28G>A has been reported in the literature in at least three individuals affected with breast cancer (e.g. Tung_2016, Akcay_2021), two of whom also carried a co-occurring a pathogenic variant (CDH1 c.521dupA, p.Asn174LysfsX25) (Tung_2016), providing support for a benign role. The variant was also found in unaffected East Asian and Hispanic control individuals (Momozawa_2018, Weitzel_2019). These report(s) do not provide unequivocal conclusions about association of the variant with Li-Fraumeni Syndrome. Publications reporting experimental evidence evaluating an impact on protein function show little to no damaging effect of this variant, including evidence from yeast assays that the variant retains transactivation capacity comparable to wild-type TP53 (e.g. Kato_2003, Giacomelli_2018). Ten submitters, including the ClinGen TP53 Variant Curation Expert Panel, have provided clinical-significance assessments for this variant to ClinVar after 2014 and classified it as either likely benign (n=5) or VUS (n=5). Based on the evidence outlined above, the variant was classified as VUS-possibly benign.
| # | Sample | Method | Observation |
|---|
| Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences |
|---|
| 1 | germline | unknown | not provided | not provided | not provided | | not provided | not provided | not provided | not provided |
